4-chloro-5-(2-chlorobenzamido)-6-(4-chlorophenylamino)pyrimidine | 686344-48-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-5-(2-chlorobenzamido)-6-(4-chlorophenylamino)pyrimidine
• 英文别名: 2-chloro-N-[4-chloro-6-(4-chlorophenylamino)pyrimidin-5-yl]benzamide；2-Chloro-N-[4-chloro-6-(4-chlorophenylamino)-pyrimidin-5-yl]-benzamide；2-chloro-N-[4-chloro-6-(4-chloroanilino)pyrimidin-5-yl]benzamide
• CAS: 686344-48-9
• 化学式: C₁₇H₁₁Cl₃N₄O
• 分子量: 393.66
• InChiKey: OMUZDRQFKDVHID-UHFFFAOYSA-N

物化性质

• 沸点：
  468.8±45.0 °C(Predicted)
• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-5-(2-chlorobenzamido)-6-(4-chlorophenylamino)pyrimidine 在 硫酸 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 8.0h， 生成 9-(4-chloro-phenyl)-8-(2-chloro-phenyl)-1-(2,2,2-trifluoro-ethyl)-1,9-dihydro-purin-6-one
  参考文献：
  名称：

  New bicyclic cannabinoid receptor-1 (CB1-R) antagonists

  摘要：

  A series of conformationally constrained bicyclic derivatives derived from SR141716 was prepared and evaluated as hCB(1)-R antagonists and inverse agonists. Optimization of the structure-activity relationships around the 2,6-dihydro-pyrazolo[4,3 -d]pyrimidin-7-one derivative 2a led to the identification of two compounds with oral activity in rodent feeding models (2h and 4a). Replacement of the PP group in 2h with other bicyclic groups resulted in a loss of binding affinity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.019
• 作为产物：
  描述：

  对氯苯胺 在 盐酸 作用下， 以 乙醇 、 N,N-二甲基乙酰胺 为溶剂， 反应 19.0h， 生成 4-chloro-5-(2-chlorobenzamido)-6-(4-chlorophenylamino)pyrimidine
  参考文献：
  名称：

  New bicyclic cannabinoid receptor-1 (CB1-R) antagonists

  摘要：

  A series of conformationally constrained bicyclic derivatives derived from SR141716 was prepared and evaluated as hCB(1)-R antagonists and inverse agonists. Optimization of the structure-activity relationships around the 2,6-dihydro-pyrazolo[4,3 -d]pyrimidin-7-one derivative 2a led to the identification of two compounds with oral activity in rodent feeding models (2h and 4a). Replacement of the PP group in 2h with other bicyclic groups resulted in a loss of binding affinity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.019

文献信息

• [EN] PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS<br/>[FR] COMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES CANNABINOIDES
  申请人：PFIZER PROD INC

  公开号：WO2004037823A1

  公开（公告）日：2004-05-06

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• [EN] BICYCLIC IMIDAZOLYL PYRIMIDIN-4-ONE CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] COMPOSES BICYCLIQUES D'IMIDAZOLYLE PYRIMIDIN-4-ONE EN TANT QUE LIGANDS DES RECEPTEURS CANNABINOIDES ET LEURS UTILISATIONS
  申请人：PFIZER PROD INC

  公开号：WO2005061505A1

  公开（公告）日：2005-07-07

  Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.

  本文描述了化学式（I）的化合物。这些化合物已被证明能够作为大麻素受体配体，并因此在治疗与动物体内大麻素受体介导相关的疾病方面具有用途。
• Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9<i>H</i>-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist
  作者：David A. Griffith、John R. Hadcock、Shawn C. Black、Philip A. Iredale、Philip A. Carpino、Paul DaSilva-Jardine、Robert Day、Joseph DiBrino、Robert L. Dow、Margaret S. Landis、Rebecca E. O’Connor、Dennis O. Scott

  DOI：10.1021/jm8012932

  日期：2009.1.22

  We report the structure−activity relationships, design, and synthesis of the novel cannabinoid type 1 (CB1) receptor antagonist 3a (CP-945,598). Compound 3a showed subnanomolar potency at human CB1 receptors in binding (Ki = 0.7 nM) and functional assays (Ki = 0.12 nM). In vivo, compound 3a reversed cannabinoid agonist-mediated responses, reduced food intake, and increased energy expenditure and fat

  我们报告了新型大麻素类型1（CB 1）受体拮抗剂3a（CP-945,598）的结构活性关系，设计和合成。化合物3a在结合（K i = 0.7 nM）和功能分析（K i = 0.12 nM）中对人CB 1受体表现出亚纳摩尔效价。在体内，化合物3a逆转了大麻素激动剂介导的反应，减少了食物的摄入，并增加了啮齿动物的能量消耗和脂肪氧化。
• [EN] A PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'UN INTERMÉDIAIRE POUR UN CARBONUCLÉOSIDE DE TRIAZOLOPYRIMIDINE
  申请人：ENANTIA S L

  公开号：WO2014023681A1

  公开（公告）日：2014-02-13

  A process for the preparation of 4,6-dihalopyrimidin-5-aminesof formula (II), or salts thereof, which comprises reacting 5-aminopyrimidin-4,6-diols of formula (III), or salts thereof, or a solvate either of the compound of formula (III) or of a salt thereof, with a halogenating agent, new intermediates useful in the preparation of the compound of formula (II) and processes for the preparation of these intermediates. The invention also refers to a process for the preparation of ticagrelor or a pharmaceutically acceptable saltthereoffrom 4,6-dihalo-2- (propylthio)pyrimidin-5-amine of formula (IIA).

  一种制备式（II）的4,6-二卤嘧啶-5-胺或其盐的方法，包括将式（III）的5-氨基嘧啶-4,6-二醇或其盐，或者化合物式（III）或其盐的溶剂与卤代试剂反应，新的中间体有助于制备式（II）的化合物以及制备这些中间体的方法。该发明还涉及一种从式（IIA）的4,6-二卤-2-(丙硫基)嘧啶-5-胺制备替卡格雷洛或其药学上可接受的盐的方法。
• Purine compounds and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040092520A1

  公开（公告）日：2004-05-13

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了化学式为（I）的化合物，它们作为大麻素受体配体，并且在动物中治疗与大麻素受体介导的疾病相关的用途。